Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Seeks to Raise $6.4M in Direct Offering

NEW YORK (GenomeWeb News) – Helicos BioSciences said after the close of the market yesterday that it has priced a registered direct offering of 6.4 million units at $1 per unit, which would provide the firm with $6.4 million in gross proceeds.

Each unit in the offering consists of one share of Helicos common stock and a warrant to buy .65 of a share of common stock. The warrants are exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share.

Helicos expects to close the offering on or around Dec. 21.

The firm plans to use the proceeds for its ongoing research and development efforts and general corporate purposes.

Helicos filed a registration statement with the US Securities and Exchange Commission in early November, in which it said that it may offer up to $50 million worth of its common stock and/or warrants to purchase common stock in one or more transactions.

In early Wednesday trade on the Nasdaq, shares of Helicos tumbled 30 percent to $.96.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.